Hydrogen-Bond Donors in Drug Design.

J Med Chem

Berwick-on-Sea, North Coast Road, Blanchisseuse, Saint George, Trinidad and Tobago.

Published: November 2022

AI Article Synopsis

  • Hydrogen-bond donors create more challenges for drug designers compared to hydrogen-bond acceptors, which are usually more numerous and have greater polarity in drug-like compounds.
  • The polarity imbalance affects the optimization of drug permeability and solubility, with the presence of hydrogen-bond donors often indicating the existence of hydrogen-bond acceptors.
  • The text also explores issues like frustrated solvation and electrostatic interactions from aligned hydrogen-bond donors and acceptors, comparing various types of hydrogen-bond donors and introducing alternatives like halogen and chalcogen-bond donors.

Article Abstract

Hydrogen-bond donors are seen to cause more problems for drug designers than hydrogen-bond acceptors. Most of the polarity in drug-like compounds comes from hydrogen-bond acceptors since they typically exceed the hydrogen-bond donors in number and are more heavily solvated on an individual basis. The implications of this polarity imbalance for optimization of permeability and aqueous solubility are discussed. A factor that should be considered in optimization of ligand recognition by targets is that the presence of a hydrogen-bond donor generally implies that a hydrogen-bond acceptor is also present (but not vice versa). Frustrated solvation and secondary electrostatic interactions result from aligned hydrogen-bond donors and acceptors, and the design opportunities presented by these phenomena are discussed. Hydrogen-bond donors based on oxygen, nitrogen and carbon are compared as target recognition elements, and halogen- and chalcogen-bond donors are discussed as hydrogen-bond donor equivalents.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.2c01147DOI Listing

Publication Analysis

Top Keywords

hydrogen-bond donors
20
hydrogen-bond
10
hydrogen-bond acceptors
8
hydrogen-bond donor
8
discussed hydrogen-bond
8
donors
5
donors drug
4
drug design
4
design hydrogen-bond
4
donors problems
4

Similar Publications

A computational study of X-H···Y binary hydrogen-bonded complexes was undertaken to examine the red- and blue-shifting behavior of three model X-H proton donors interacting with a series of Lewis bases: Y = NH, NCLi, NCH, NCF, CH, BF, CO, N and Ne. Two of these proton donors, FArH and FCH, have blue-shifting tendencies, while the third, FH, has red-shifting tendencies. A perturbation theory model for frequency shifts that was derived many years ago was employed to partition the predicted frequency shift into the sum of two components, one dependent on the second derivative of the interaction energy with respect to X-H displacement and the other dependent on the X-H bond length change in the binary complex.

View Article and Find Full Text PDF

Binuclear silver(I) and copper(I) complexes, and , with bridging diphenylphosphine ligands were prepared. In , the silver(I) center is located inside a trigonal plane composed of three phosphorus donors from three separate and bridging dppm ligands. The fourth coordination site is filled with neighboring silver(I) ions.

View Article and Find Full Text PDF

In biological systems, heme-copper oxidase (HCO) enzymes play a crucial role in the oxygen reduction reaction (ORR), where the pivotal O-O bond cleavage of the (heme)Fe-peroxo-Cu intermediate is facilitated by active-site (peroxo core) hydrogen bonding followed by proton-coupled electron transfer (PCET) from a nearby (phenolic) tyrosine residue. A useful approach to comprehend the fundamental relationships among H-bonding/proton/H-atom donors and their abilities to induce O-O bond homolysis involves the investigation of synthetic, bioinspired model systems where the exogenous substrate properties (such as p and bond dissociation energy (BDE)) can be systematically altered. This report details the reactivity of a heme-peroxo-copper HCO model complex (LS-4DCHIm) toward a series of substituted catechol substrates that span a range of p and O-H bond BDE values, exhibiting different reaction mechanisms.

View Article and Find Full Text PDF

The well-known inhibitory strength of 3d metal Schiff base complexes against urease enzymes has long been acknowledged, but their untapped potential to act as ureolytic mimics of active metallobiosites remained unexplored. To break the new ground, we present pyrrolidine-based mononuclear Ni(II)-azide complex {[NiL(HL)(N)]·1.5(HO)} using the N,N,O donor ligand, namely ()-4-bromo-2-(((2-(pyrrolidin-1-yl)ethyl)imino)methyl)phenol.

View Article and Find Full Text PDF

p Matching Enables Quantum Proton Delocalization in Acid-1-Methylimidazole Binary Mixtures.

J Chem Inf Model

January 2025

Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey 08854, United States.

Short hydrogen bonds (SHBs), characterized by donor-acceptor heteroatom separations below 2.7 Å, are prevalent in condensed-phase systems. Recently, we identified SHBs in nonaqueous binary mixtures of acetic acid and 1-methylimidazole (MIm), where electronic and nuclear quantum effects facilitate extensive proton delocalization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!